Drug intelligence / Profile preview

Ganshuang Keli

Development stage: Phase 1
Lead developer: Buchang Pharmaceuticals
Administration: Oral

Overview

**Ganshuang Keli** is an oral Chinese proprietary herbal medicine supplied as granules for chronic liver disease. It is a multi-herb traditional Chinese medicine formulation manufactured by Baoding Buchang Tianhao Pharmaceutical and has been evaluated as an adjunctive treatment for chronic hepatitis, liver fibrosis, and hepatitis B-associated cirrhosis, including in combination with silybin meglumine or entecavir. Its pharmacology is not attributable to a single defined molecular active ingredient or validated primary drug target; reported therapeutic intent is hepatoprotection and attenuation of liver inflammation and fibrotic progression.

Brand names: Buchang步长
Other names: Ganshuang granuleGanshuang granules肝爽颗粒

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on Ganshuang Keli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ganshuang Keli.

Explore the full profile